BCRX
Price
$9.29
Change
+$0.15 (+1.64%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
2.37B
37 days until earnings call
Intraday BUY SELL Signals
CRNX
Price
$35.89
Change
+$0.51 (+1.44%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
3.79B
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCRX vs CRNX

BCRX vs CRNX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BCRX vs. CRNX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Buy and CRNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (BCRX: $9.14 vs. CRNX: $35.38)
Brand notoriety: BCRX: Notable vs. CRNX: Not notable
BCRX represents the Pharmaceuticals: Generic, while CRNX is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 167% vs. CRNX: 81%
Market capitalization -- BCRX: $2.37B vs. CRNX: $3.73B
BCRX [@Pharmaceuticals: Generic] is valued at $2.37B. CRNX’s [@Biotechnology] market capitalization is $3.73B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CRNX’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 2 bearish.
  • CRNX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than CRNX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а +0.88% price change this week, while CRNX (@Biotechnology) price change was +0.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.70%. For the same industry, the average monthly price growth was +0.08%, and the average quarterly price growth was +8.31%.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 30, 2026.

CRNX is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.79B) has a higher market cap than BCRX($2.37B). BCRX YTD gains are higher at: 17.179 vs. CRNX (-23.996). BCRX has higher annual earnings (EBITDA): -377.5M vs. CRNX (-541.62M). CRNX has more cash in the bank: 1.29B vs. BCRX (238M). CRNX has less debt than BCRX: CRNX (47.9M) vs BCRX (818M). BCRX has higher revenues than CRNX: BCRX (886M) vs CRNX (18.1M).
BCRXCRNXBCRX / CRNX
Capitalization2.37B3.79B62%
EBITDA-377.5M-541.62M70%
Gain YTD17.179-23.996-72%
P/E Ratio7.46N/A-
Revenue886M18.1M4,895%
Total Cash238M1.29B18%
Total Debt818M47.9M1,708%
FUNDAMENTALS RATINGS
BCRX vs CRNX: Fundamental Ratings
BCRX
CRNX
OUTLOOK RATING
1..100
2212
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
48
Fair valued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
5458
P/E GROWTH RATING
1..100
46100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (19) in the Biotechnology industry is in the same range as CRNX (48) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (69) in the Pharmaceuticals Major industry is in the same range as BCRX (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to BCRX’s over the last 12 months.

CRNX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as BCRX (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (54) in the Biotechnology industry is in the same range as CRNX (58) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew similarly to CRNX’s over the last 12 months.

BCRX's P/E Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew somewhat faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCRNX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 14 days ago
80%
Bearish Trend 13 days ago
78%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signal:
Gain/Loss:
CRNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FCUS46.690.94
+2.06%
Pinnacle Focused Opportunities ETF
IVOO129.080.55
+0.43%
Vanguard S&P Mid-Cap 400 ETF
AURU11.71N/A
N/A
Tradr 2X Long AUR Daily ETF
GARP81.25-0.08
-0.10%
iShares MSCI USA Quality GARP ETF
NTSI47.44-0.19
-0.40%
WisdomTree International Efficnt Cr ETF

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+1.67%
VCYT - BCRX
46%
Loosely correlated
-0.82%
CRNX - BCRX
42%
Loosely correlated
-1.37%
HOWL - BCRX
39%
Loosely correlated
+5.35%
ROIV - BCRX
38%
Loosely correlated
-0.64%
BEAM - BCRX
38%
Loosely correlated
+4.07%
More

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with RNA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.37%
RNA - CRNX
44%
Loosely correlated
+2.21%
XNCR - CRNX
44%
Loosely correlated
+10.84%
GLUE - CRNX
42%
Loosely correlated
+1.91%
KURA - CRNX
42%
Loosely correlated
+4.33%
MLTX - CRNX
41%
Loosely correlated
+15.33%
More